Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
NCT04956276 · Alexion Pharmaceuticals, Inc. · PHASE2 · withdrawn · last registry update 2022-02-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to terminate program” | – | Registry record, Alexion Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FCGRT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-12Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT05681715)
- 2022-11-03Results posted on the registry: UCB Biopharma SRL, Rozanolixizumab (NCT04051944)
- 2022-09-01Phase 3 first posted: Immunovant Sciences GmbH, Batoclimab + Placebo (NCT05524571)
- 2022-08-26Phase 3 first posted: Immunovant Sciences GmbH, Batoclimab (NCT05517447)
- 2022-08-26Phase 3 first posted: Immunovant Sciences GmbH, Batoclimab + Placebo (NCT05517421)
- 2022-06-03Phase 3 first posted: Immunovant Sciences GmbH, Batoclimab 680 mg SC weekly + Batoclimab 340 mg SC weekly (NCT05403541)
- 2022-04-14Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT05327114)
- 2022-04-04Results posted on the registry: UCB Biopharma S.P.R.L., Rozanolixizumab (NCT03861481)
- 2022-03-03Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab (NCT05265273)
- 2022-02-08Results posted on the registry: argenx, ARGX-113 + Placebo (NCT03669588)
- 2021-09-30Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT05063162)
- 2021-08-03Results posted on the registry: UCB Biopharma S.P.R.L., UCB7665 (NCT03052751)
- 2021-07-07Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT04951622)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision